Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Alzheimer's Disease

Free Subscription Articles published in Lancet Neurol Retrieve available abstracts of 48 articles: HTML format

Single Articles

December 2025
1. RABINOVICI GD
   Progress in Alzheimer's disease: The Lancet Series.
   Lancet Neurol. 2025;24:991-992.
   PubMed    
   
   
   
2. SCHOLZ SW, Okubadejo NU, Prakash P, Liddelow SA, et al
   Advances in the genetics and pathology of Lewy body dementia.
   Lancet Neurol. 2025;24:1026-1037.
   PubMed     Abstract available
   
   
   
3. JACK CR JR, Hu M, Wiste HJ, Knopman DS, et al
   Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study.
   Lancet Neurol. 2025;24:1016-1025.
   PubMed     Abstract available
   
   
   November 2025
4. BOON BDC, Piura YD, Moloney CM, Chalk JL, et al
   Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study.
   Lancet Neurol. 2025;24:931-944.
   PubMed     Abstract available
   
   
   
5. IWATSUBO T
   Neuropathology of Alzheimer's disease after anti-amyloid beta antibody treatment.
   Lancet Neurol. 2025;24:897-899.
   PubMed    
   
   
   September 2025
6. RAFII MS, Schlachetzki Z, Barroeta I, Head E, et al
   Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology.
   Lancet Neurol. 2025;24:753-762.
   PubMed     Abstract available
   
   
   
7. THERRIAULT J, Brum WS, Trudel L, Macedo AC, et al
   Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
   Lancet Neurol. 2025;24:740-752.
   PubMed     Abstract available
   
   
   
8. RYAN NS
   Alzheimer's disease in Down syndrome: progress and promise.
   Lancet Neurol. 2025;24:717-718.
   PubMed    
   
   
   
9. KESHAVAN A, Algeciras-Schimnich A
   Plasma phosphorylated tau for Alzheimer's disease diagnosis.
   Lancet Neurol. 2025;24:715-717.
   PubMed    
   
   
   August 2025
10. LI Y, Llibre-Guerra JJ, Supnet C, Atri A, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease - Authors' reply.
    Lancet Neurol. 2025;24:635-636.
    PubMed    
    
    
    
11. CHENG Y, Zhang Y, Zhang S, Shang H, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease.
    Lancet Neurol. 2025;24:634.
    PubMed    
    
    
    
12. WALSH S, Howard R, Richard E, Milne R, et al
    Interpreting the evidence on gantenerumab for dominantly inherited Alzheimer's disease.
    Lancet Neurol. 2025;24:634.
    PubMed    
    
    
    July 2025
13. TEUNISSEN C, Duits F
    Plasma biomarkers for diagnosis and prognosis in Down syndrome-related Alzheimer's disease.
    Lancet Neurol. 2025;24:561-562.
    PubMed    
    
    
    June 2025
14. MARINO C, Malotaux V, Giudicessi A, Aguillon D, et al
    Protective genetic variants against Alzheimer's disease.
    Lancet Neurol. 2025;24:524-534.
    PubMed     Abstract available
    
    
    
15. THE LANCET NEUROLOGY
    A genetic framework for Alzheimer's disease prevention.
    Lancet Neurol. 2025;24:471.
    PubMed    
    
    
    May 2025
16. MATAR E, Halliday GM
    Biological effects of pathologies in Lewy body diseases: why timing matters.
    Lancet Neurol. 2025;24:441-455.
    PubMed     Abstract available
    
    
    April 2025
17. BATEMAN RJ, Li Y, McDade EM, Llibre-Guerra JJ, et al
    Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
    Lancet Neurol. 2025;24:316-330.
    PubMed     Abstract available
    
    
    
18. SCHOTT JM
    Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time?
    Lancet Neurol. 2025;24:279-281.
    PubMed    
    
    
    February 2025
19. BLANQUIE O, Guizzaro L, Herold R, Haberkamp M, et al
    EU regulatory horizons for Alzheimer's disease.
    Lancet Neurol. 2025;24:96-97.
    PubMed    
    
    
    
20. MASTERS CL
    Should the preclinical stage of Alzheimer's disease be disclosed?
    Lancet Neurol. 2025;24:94-95.
    PubMed    
    
    
    January 2025
21. THE LANCET NEUROLOGY
    Bridging the diagnostic gap in Alzheimer's disease.
    Lancet Neurol. 2025;24:1.
    PubMed    
    
    
    December 2024
22. SCHWORER EK, Zammit MD, Wang J, Handen BL, et al
    Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.
    Lancet Neurol. 2024;23:1214-1224.
    PubMed     Abstract available
    
    
    
23. HUNDAL H
    Frank Longo: taking on Alzheimer's disease.
    Lancet Neurol. 2024;23:1188.
    PubMed    
    
    
    
24. RAFII MS
    The amyloid clock: mapping Alzheimer's disease in Down syndrome.
    Lancet Neurol. 2024;23:1173-1174.
    PubMed    
    
    
    October 2024
25. STIRRUPS R
    Navigating the roads ahead for Alzheimer's disease.
    Lancet Neurol. 2024;23:971.
    PubMed    
    
    
    
26. HYMAN BT
    Amyloid removal and the appearance of brain volume loss.
    Lancet Neurol. 2024;23:957-958.
    PubMed    
    
    
    
27. BELDER CRS, Boche D, Nicoll JAR, Jaunmuktane Z, et al
    Brain volume change following anti-amyloid beta immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy.
    Lancet Neurol. 2024;23:1025-1034.
    PubMed     Abstract available
    
    
    September 2024
28. THE LANCET NEUROLOGY
    The evolving paradigm of Alzheimer's disease diagnosis.
    Lancet Neurol. 2024;23:845.
    PubMed    
    
    
    August 2024
29. OHRY A
    Ezio Giacobini: a leader in Alzheimer's disease research.
    Lancet Neurol. 2024;23:768.
    PubMed    
    
    
    July 2024
30. SCHULTZ SA, Liu L, Schultz AP, Fitzpatrick CD, et al
    gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00236.
    PubMed     Abstract available
    
    
    
31. POTIER MC, Steiner H, Chavez-Gutierrez L
    Amyloid beta, gamma-secretase, and familial Alzheimer's disease.
    Lancet Neurol. 2024 Jul 26:S1474-4422(24)00292.
    PubMed    
    
    
    June 2024
32. KAPASI A, Schneider JA
    Speculation on the transmissibility of Alzheimer's disease.
    Lancet Neurol. 2024;23:555-556.
    PubMed    
    
    
    May 2024
33. WISCH JK, McKay NS, Boerwinkle AH, Kennedy J, et al
    Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2024;23:500-510.
    PubMed     Abstract available
    
    
    
34. NORDBERG A
    Insights into the progression of genetic Alzheimer's disease from tau PET.
    Lancet Neurol. 2024;23:453-454.
    PubMed    
    
    
    March 2024
35. FRISONI GB, Festari C, Massa F, Cotta Ramusino M, et al
    European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.
    Lancet Neurol. 2024;23:302-312.
    PubMed     Abstract available
    
    
    
36. THE LANCET NEUROLOGY
    Dementia diagnosis in the anti-amyloid era.
    Lancet Neurol. 2024;23:219.
    PubMed    
    
    
    February 2024
37. CHAPLEAU M, La Joie R, Yong K, Agosta F, et al
    Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.
    Lancet Neurol. 2024;23:168-177.
    PubMed     Abstract available
    
    
    
38. REIMAN EM, Cummings JL, Langbaum JB, Mattke S, et al
    A chance to prevent Alzheimer's disease sooner than you think.
    Lancet Neurol. 2024;23:144-145.
    PubMed    
    
    
    
39. BEJANIN A, Villain N
    Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease.
    Lancet Neurol. 2024;23:127-128.
    PubMed    
    
    
    January 2024
40. DELRIEU J, Andrieu S, Vellas B
    Dementia research in 2023: the year of anti-amyloid immunotherapy.
    Lancet Neurol. 2024;23:13-15.
    PubMed    
    
    
    December 2023
41. RANSCOMBE P
    Powerful series profiles rare forms of dementia.
    Lancet Neurol. 2023;22:1112.
    PubMed    
    
    
    November 2023
42. SCHLEPCKOW K, Morenas-Rodriguez E, Hong S, Haass C, et al
    Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease.
    Lancet Neurol. 2023;22:1048-1060.
    PubMed     Abstract available
    
    
    September 2023
43. JAGUST WJ, Teunissen CE, DeCarli C
    The complex pathway between amyloid beta and cognition: implications for therapy.
    Lancet Neurol. 2023;22:847-857.
    PubMed     Abstract available
    
    
    July 2023
44. BELDER CRS, Schott JM, Fox NC
    Preparing for disease-modifying therapies in Alzheimer's disease.
    Lancet Neurol. 2023 Jul 14:S1474-4422(23)00274.
    PubMed    
    
    
    
45. FRISONI GB
    Complexity is the simple truth about Alzheimer's disease.
    Lancet Neurol. 2023 Jul 13:S1474-4422(23)00176.
    PubMed    
    
    
    June 2023
46. THE LANCET NEUROLOGY
    Treatment for Alzheimer's disease: time to get ready.
    Lancet Neurol. 2023;22:455.
    PubMed    
    
    
    
47. MASON M, Bacioglu M, Vivacqua G, Spillantini MG, et al
    Targeting tau degradation: a viable therapeutic approach?
    Lancet Neurol. 2023;22:462-464.
    PubMed    
    
    
    May 2023
48. LANGWORTH-GREEN C, Patel S, Jaunmuktane Z, Jabbari E, et al
    Chronic effects of inflammation on tauopathies.
    Lancet Neurol. 2023;22:430-442.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.